The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.
News|Videos|June 17, 2024
Long-Term Follow up for Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutated Melanoma: Final Results of the COMBI-AD Study
COMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.
Advertisement
Advertisement
Related to this article
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma
2
FDA Grants RMAT and Fast Track Designations to Cema-Cel for First-Line LBCL
3
Dr Hashmi on the Identification of Candidates for CAR T-Cell Therapy in Early R/R Myeloma
4
Dr Secord on Combining Mocertatug Rezetecan With Dostarlimab in Endometrial Cancer
5